A Study of Trastuzumab Deruxtecan in People With Non-Small Cell Lung Cancer

Summary

The purpose of this study is to find out how many people with HER2-amplified or HER2-mutated non-small cell lung cancer (NSCLC) experience a decrease in tumor viability when they receive trastuzumab deruxtecan before routine surgery to remove tumors.

Timeline

Start

2026-02-13

Primary completion

2027-02-13

Completion

2027-02-13

Drugs

Indications